Wel­come back to End­points Week­ly — thanks for start­ing your Sat­ur­day with us. It was a busy week in the bio­phar­ma world. FDA Com­mis­sion­er Mar­ty Makary … ...

Iovance Therapeutics’ stock dropped more than 44% on Friday afternoon, a day after the company slashed its 2025 sales ...

Lonza said on Friday it does not expect any 'material financial impact' from current and potential pharma-specific tariffs.

Illumina on Thursday said the SEC has closed its investigation into the company's $8 billion purchase of Grail and doesn't ...

Endpoints platform launches new profile system with improved account management features, including streamlined newsletter ...

Patrik Jonsson becomes International president, Ilya Yuffa leads USA division, Kenneth Custer takes over Cardiometabolic ...

Boston-based Verastem Oncology on Thursday won accelerated approval from the FDA for Avmapki Fakzynja as a second-line ...

AstraZeneca lost its challenge to Medicare drug price negotiations in the first appeals court ruling on the merits of the ...

Revolution Medicines reports positive data for KRAS-targeting cancer drug elironrasib, showing higher response rates vs Amgen ...

The FDA is still reviewing a label expansion for GSK’s respiratory drug Nucala in chronic obstructive pulmonary disease ...

Lan­theus fi­nal­ly came clean about the fate of its ex­per­i­men­tal ra­dio­phar­ma­ceu­ti­cal for prostate can­cer, ...

The AI-fo­cused biotech in­sitro has laid off 22% of its work­force, the com­pa­ny said in a Thurs­day state­ment. Found­ed ...